Exposição in utero ao desregulador endocrino bisfenol A e ao agente quimiopreventivo indol-3-carbinol: efeitos sobra a morfogênese e a suscetibilidade à carcinogênese prostática

Pós-graduação em Biologia Geral e Aplicada - IBB

Cintilografia de mamas com sestamibi-99mTc na avaliação da resposta quimioterápica pré-operatória: análise quantitativa

Pós-graduação em Ginecologia, Obstetrícia e Mastologia - FMB

Efeitos da Ginkgo biloba sobre o desenvolvimento e o crescimento de neoplasias de mama em ratas da linhagem Sprague-Dawley

Pós-graduação em Patologia - FMB

Desenvolvimento de um escore preditor da eficácia do tratamento quimioterápico pré-operatório em mulheres com carcinoma de mama localmente avançado

Pós-graduação em Ginecologia, Obstetrícia e Mastologia - FMB

Efeito imunomodulador de baixas concentrações de antineoplásicos

Pós-graduação em Patologia - FMB

Exposição in utero ao desregulador endócrino Bisfenol A e à Genisteína: efeitos sobre a morfogênese e a susceptibilidade a carcinogênese prostática em ratos Sprague-Dawley

Pós-graduação em Patologia - FMB

Efeito da suplementação de vitamina D no desenvolvimento de lesões pré-neoplásicas quimicamente induzidas em ratos Wistar macho

Pós-graduação em Biologia Geral e Aplicada - IBB

Análise histopatológica de biópsia prostática guiada pelo ultrassom transretal com 10 e 12 fragmentos: ensaio clínico prospectivo controlado

Pós-graduação em Bases Gerais da Cirurgia - FMB

Eletroquimioterapia em cães e gatos

The eletrochemotherapy is a new treatment option for neoplasms that involves the application of chemotherapeutic drugs endovenously or intralesionally, associated with local severe and short duration electrical pulses. The electrical pulses promote destabilization of the cell membrane, causing transitory pore formation and facilitating the entry of chemotherapeutic agents inside the cells, increasing its cytotoxicity. This therapy allows for lower doses of chemotherapy drugs compared to conventional chemotherapy, resulting in the decrease of side effects and costs of treatment. The eletrochemotherapy has proved effective in the treatment of cancer regardless of its histological origin and location. This review aims to highlight possibilities to use this treatment in Veterinary Oncology

Braquiterapia com sementes de iodo-125: manufatura e tratamento

According to the National Institute of Cancer – INCA, 466.730 new cancer cases will occur in Brazil in 2009. Prostate and Lung cancer in man are the most incident types (in exception of the non-melanoma cancer). The brachytherapy with 125-iodine sources is an important method of prostate cancer treatment. The implant with iodine-125 seeds uses aproximately 100 seeds that are imported impossibilitating the treatment in large scale. For this reason, a multidisciplinary group was created at the Energetic and Nuclear Research Institute – Radiation Technology Center (IPEN –CTR / SP) to develop a national 125-iodine source and established a facility for local production. The seeds manufacture in Brazil will diminish the cost of treatment and prostate brachytherapy will be offered to more patients. This work aim is to observe and discuss the methods used in seeds manufacture there are being developed in Brazil and to present an prostate cancer case folloied in A.C. Camargo Hospital. The 125-iodine is adsorbed in an silver wire, then deposited at titanium coat. The weld is made by an process of plasm sealing. The seeds goes through several test to guarantee that there is no leakage. The result is an high quality and cheaper product. The implant tecnique is an fast and save procedure. The medical physicst preplan the case to stipulate the quantity of seeds there will be used. At the dat of the implant the medical physicst replan the procedure due to changes of volume in the organ. That assure the correct dose distribution in the target. Besides, the 125-iodine low energy is absorbed at the volume of interrest saving sourronding healthy tissues such as the rectum and the urethra

Efeito das baixas concentrações de agentes antineoplásicos sobre linfócitos humanos de sangue periférico

Our previous studies have shown that low concentrations (noncytotoxics) of antineoplastic agents modulate positively the dendritic cells, favoring their in vitro maturation and improving their antigen presenting function. The effects on colorectal cancer cells (HCT-116) were also investigated and we have observed an increased immunogenicity and susceptibility to cytotoxic T cells. Thereby, this study aimed to investigate the effect of 5-fluorouracil (5-FU) an azacitidine (AZA), in minimum effective and noncytotoxic concentrations on lymphocytes of healthy donors. In this study we have analyzed the cytotoxic effect of drugs at these concentrations as well as the proliferative ability of lymphocytes. In vitro production of IL-10 and IFN-γ has been also evaluated. We have observed that low concentrations of those chemotherapeutic agents are not cytotoxic for lymphocytes. However, the minimum effective concentrations (5-FU: 0,410±0,088 e AZA: 0,757±0,233; p<0, 05) have reduced the cell number. Proliferative activity of allogeneic lymphocytes in a mixed reaction (MLR) was not affected by the treatment. The cytokine production was not affected by the treatments, either. In conclusion, low concentrations of 5-FU and AZA has no deleterious effects on human peripheral blood lymphocytes and seems to be safe for combinatory administration with DC vaccines

Potential quimioprotetor do DIM (3, 3' - Di-indolil-metano) e da Genisteína em linhagens de células tumorais prostáticas humanas LNCaP e PC-3 expostas ao Bisfenol A

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Reabilitação do assoalho pélvico em pacientes com incontinência urinária pós prostatectomia radical

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Tendências e projeções da mortalidade pelos cânceres específicos ao gênero no Brasil

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES

Estudo da influência da morfologia de nanopartículas de sílica mesoporosa na liberação do anticancerígeno indol-3-carbinol

Dissertação (mestrado)—Universidade de Brasília, Faculdade de Ceilândia, Programa de Pós-graduação em Ciências e Tecnologias em Saúde, 2015.